FDMT
4D Molecular Therapeutics, Inc.
$10.14
+2.11%
2026-05-08
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Key Fundamentals
Forward P/E
-2.61
EPS (TTM)
$-2.42
ROE
-27.6%
Revenue Growth (YoY)
8508900.0%
Profit Margin
-164.4%
Debt/Equity
4.24
Price/Book
1.10
Beta
2.76
Market Cap
$506.0M
Avg Volume (10D)
651K
Recent Breakout Signals
No recent breakout signals detected for FDMT.
Recent Price Range (60 Days)
60D High
$10.88
60D Low
$7.96
Avg Volume
713K
Latest Close
$10.14
Get breakout alerts for FDMT
Sign up for Breakout Scanner to receive daily notifications when FDMT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
4D Molecular Therapeutics, Inc. (FDMT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors FDMT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. FDMT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.